Immunovia AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMVF research report →
Companywww.immunovia.com
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer.
- CEO
- Jeff Borcherding
- IPO
- 2019
- Employees
- 9
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $6.11M
- P/E
- -1.20
- P/S
- 70.74
- P/B
- 2.75
- EV/EBITDA
- -0.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -3677.48%
- Op Margin
- -8602.18%
- Net Margin
- -11594.78%
- ROE
- -353.07%
- ROIC
- -168.26%
Growth & Income
- Revenue
- $683.28K · -26.61%
- Net Income
- $-145,548,968 · -90.16%
- EPS
- $-0.42 · 54.84%
- Op Income
- $-79,304,554
- FCF YoY
- 19.17%
Performance & Tape
- 52W High
- $0.15
- 52W Low
- $0.02
- 50D MA
- $0.02
- 200D MA
- $0.04
- Beta
- 0.95
- Avg Volume
- 74.8
Get TickerSpark's AI analysis on IMMVF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IMMVF Coverage
We haven't published any research on IMMVF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMMVF Report →